Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by Bucknelly21on Jan 08, 2021 12:48pm
248 Views
Post# 32254743

Just to add to the credibility talk

Just to add to the credibility talkI will say one thing, Thtx has not taken on anything that seems to have not worked out as far as r&d. Sales clearly not their strong point but gettting projects to the finish line is definitely very much their forte. After yesterday's pr I felt like all the doubts I had about a lot of where they were headed are put to rest. And like spceo and wino ect have pointed out its only a matter of time before that valuation that we all know is right comes to life. It makes me feel that when they play things so close to the chest ie nash and oncology they already have a good idea of where it's heading. I would say you can back the truck up for any price under double digits this year. Oncology will be a home run as Thtx has proven they don't get involved with a project without feeling extremely confident in the outcome as far as dealing with the agencies. Would be nice to see a better reaction to yesterday but it's on its way. I was always agreeing with everyone saying be patient because I was trying to cling onto some hope for this company because I had such a big position relative to my situation. But now I actually really think that this has a good chance to be one of those 5 chances in the market that a person has to really do some damage. Analysis on this board has been pretty spot on, only a matter of time before they run out of Cheetos and have to do some actual work. 2021 is the breakout 
<< Previous
Bullboard Posts
Next >>